CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2015—Agena Bioscience released the LungFusion Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. Using as little as 10 ng of complementary DNA template, the research-use-only, single-well panel identifies expressed translocations of known clinical relevance in formalin-fixed, paraffin-embedded and fresh frozen tissue samples. The MassArray-based assay aims to provide a simple, sensitive alternative to conventional screening methods such as immunohistochemistry stains and fluorescence in situ hybridization.
The LungFusion panel contains built-in controls to simultaneously assess RNA quality, report DNA contamination, and determine the relative amount of lung tissue present in the sample. Agena Bioscience’s software automatically reports translocation status for each sample as well as a confidence score.
Agena Bioscience, 858-882-2800